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SUMMARY
Cancer is one of the most common fatal diseases in humans nowadays. About 20 million new cancer cases 
are expected in the next two decades worldwide. The development of new chemotherapeutic agents 
with improved properties is presently the main challenge in the medicinal chemistry. 
Cisplatin was introduced to oncology in 1978 as first chemotherapeutic agent regarding its specific 
interaction with DNA, leading to its damage and causing the cell death. Since the first application of cisplatin 
in cancer therapy, there has been a growing interest in new metal-based compounds, in particular platinum 
and ruthenium complexes, with better anticancer activity and less side-effects compared to cisplatin. 
Carboplatin and oxaliplatin have shown promising action against some types of cancer, which are resistant 
to cisplatin. With the aim to overcome cross-resistance to these Pt(II) drugs, bioavailable platinum complexes 
(satraplatin and picoplatin) firstly found application as orally administered drugs, as well as some combined 
therapies of Pt(II) drugs (cisplatin, picoplatin) with specific resistant modulators. In recent years, novel 
polymer and liposomal formulations of platinum drugs (prolindac, lipoplatin, lipoxal, aroplatin) have been 
designed with strategy to improve drug delivery to target cancer cells and reduce toxicity. Complexes 
based on ruthenium have great potential to become leading candidates for the medical use in anticancer 
therapy. Some of these compounds have shown good anticancer activity, both in vitro and in vivo and two 
of them (KP1019 and NAMI-A) have passed clinical trials and given promising results.
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For thousands of years, many metal-based 
compounds have had application as therapeutic 
agents. Application of zinc and silver in heal-
ing of wounds and infection prevention dates 
back to ancient times [1]. Nowadays, cisplatin 
and auranofin, two important drugs based on 
platinum and gold metals, are widely used for 
the treatment of cancer and rheumatoid arthri-
tis, respectively [2, 3]. Although platinum and 
ruthenium are non-biogenic elements, many of 
their complexes have shown potential applica-
tion in cancer therapy [4, 5]. 
Due to their diversity, various metal com-
plexes have shown therapeutic effect in treat-
ment of many diseases [2–8]. Currently, com-
plexes of Cu(II), Zn(II), Ni(II) and Co(II) have 
found application as antimicrobial and antiviral 
agents [6, 7]. Some polyoxometalate complexes 
of early transition metals (W, V, Mo) have also 
shown promising medical application due to 
their antimicrobial, antiacetylcholinesterase 
and anticancer effects [8, 9].
Immediately after cardiovascular diseases, 
cancer is the leading cause of death in humans 
worldwide [4]. In recent years, the focus of 
interest in medicinal chemistry has been ap-
plication of metal complexes in treatment of 
malignant diseases [2–5]. Cancer therapy in-
cludes the surgical removal of tumor, radiation 
therapy and chemotherapy. Currently, diverse 
platinum complexes have found application in 
cancer therapy as chemotherapeutic agents, 
while many new synthesized complexes of 
gallium, gold, titanium, and ruthenium are in-
tensively studied. Some ruthenium complexes 
attract special attention due to their promis-
ing results in clinical trials [5]. The main goal 
of this paper is to consider current knowledge 
of the platinum and ruthenium complexes re-
lated to anticancer therapy. Some of platinum 
complexes are clinically approved, while some 
of them including the ruthenium complexes 
have entered or may enter clinical trials soon.
PLATINUM ANTICANCER COMPLEXES
Despite thousands of novel platinum complexes, 
only three of them are presently in clinical use 
in anticancer therapy: cisplatin, carboplatin, and 
oxaliplatin [2, 4, 5]. These drugs are adminis-
trated intravenously, and beside their good anti-
cancer activity, they show some side-effects such 
as toxicity and acquired resistance which signifi-
cantly limits their clinical application [2, 4, 5].
For nearly 40 years, cisplatin (cis-diammi-
nodichloro)platinum(II), cis-[PtCl2(NH3)2] 
(Figure 1) has been the most widely used che-
motherapeutics in oncology, and it is being ad-
ministered to ca 50% of all cancer patients [4, 
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5, 10]. Cisplatin, whose trade name is Platinol, is a leading 
anticancer drug used in therapy of testicular, ovarian, lung, 
head, neck, and bladder carcinomas. It is square-planar 
complex whose activity is reflected by hydrolysis of chlo-
ride ligands in the cells. The complex binds to DNA across 
nitrogen N7 atoms of nucleobases (guanine and adenine) 
forming stable intrastrand links (1,2-GpG and 1,2-ApG) 
(Figure 1) [2, 4]. The DNA cross-linking leads to distort 
conformations, blocks replication, prevents transcription 
and triggers apoptosis. Unfortunately, cisplatin shows 
some disadvantages such as cumulative toxicity including 
nephrotoxicity, neurotoxicity, ototoxicity, nausea, hair loss, 
and treatment-induced resistance [2, 4, 5]. Resistance to 
cisplatin results from complex mechanisms at molecular 
and cellular levels including reduction in cellular accu-
mulation, increased inactivation by SH-proteins, altered 
expression of regulatory genes, increased levels of DNA 
damage repair and increased adduct tolerance [11]. These 
drawbacks encourage the development of novel cisplatin 
analogues with improved properties.
Carboplatin (cis-diammine(1,1-cyclobutanedicarbox-
ylato)platinum(II), whose trade name is Paraplatin, is the 
second generation of Pt(II) drugs which, compared to cis-
platin, has a bidentate dicarboxylate ligand instead of two 
labile chloride ligands (Figure 1). Higher stability of this 
complex causes consequently lower toxicity leading to a 
long-lasting effect. To be more precise, 
carboplatin needs more time to reach 
the target biomolecules (retention half-
life of 30 hours) compared to cisplatin 
(1.5–6 hours), forming the same type of 
DNA adducts [2, 4, 5, 12]. Carboplatin 
has showed lower toxicity than cispla-
tin, an insignificant nephrotoxicity in 
particular, being effective against some 
types of cancer that are not sensitive to 
cisplatin [2, 4, 5, 12].
Oxaliplatin[oxalato(2-)-O,O’]
[1R,2R-cyclohexanediamine-N,N’]
platinum(II), whose trade name is 
Eloxatin, was the first drug to success-
fully overcome resistance to cisplatin 
due to the replacement of two amine 
ligands in cisplatin with stable biden-
tate ligand, (1R,2R) -cyclohexane-1,2-
diamine (R,R-DACH) (Figure 1) [2, 4, 
5, 13]. Oxaliplatin is a third generation 
of Pt(II) compounds whose high cyto-
toxicity and noncross-resistance can be 
attributed to voluminous, hydrophobic 
DACH ligand that interacts signifi-
cantly with major groove of DNA and 
prevents repair pathway. High cyto-
toxicity of oxaliplatin to cancer cells is 
caused by formation of more damaging 
Pt-DNA adducts, mainly intrastrand 
1,2-GpG linked [13].
There are four platinum complexes 
that currently have importance in ad-
vance clinical trials due to either their oral bioavailability 
(satraplatin and picoplatin) [14] or to improved polymer 
and liposomal drug delivery systems with lower toxicity 
(prolindac and lipoplatin) [15–18].
Satraplatin (bis-(acetato-O)amminedichloro(cyclohex- 
ylamine)platinum(IV), whose trade name is Orplatna, is 
a Pt(IV) octahedral complex with two axial monodentate 
acetate ligands, which enable its bioavailability as the first 
platinum oral administrated therapeutic agent (Figure 
1) [4, 5, 14]. Lower toxicity and lower side effects of sa-
traplatin come from less activity of Pt(IV) compared to 
Pt(II) complexes (cisplatin, carboplatin, oxaliplatin), its 
rapid absorption through gastrointestinal mucosa and re-
duction to at least six different Pt(II) metabolites, out of 
which cis-amminedichloro-(cyclohexylamine)platinum(II) 
is the most abundant [14]. This metabolite is bound to 
DNA by 1,2-intrastrand cross-links inducing apoptosis. 
All metabolites of satraplatin mainly bind to plasma pro-
teins with negligible percentage of their decomposition to 
free platinum. Satraplatin overcame Phase III clinical trials 
showing significant anticancer activity to several platinum-
resistant human cancer cell lines, including lung, ovarian, 
and prostate cancer [14].
Picoplatin(cis-(amminedichloro-2-methylpyridine)
platinum(II) is an analog of cisplatin, where an ammine 
ligand is substituted with bulkier 2-methylpyridine re-
Figure 1. Development pathway of platinum drugs in cancer therapy
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sponsible for steric shielding around platinum(II) center 
(Figure 1). This ligand prevents nucleophilic attacks of 
SH-proteins such as glutathione, and overcomes cisplatin 
resistance. To be more precise, picoplatin is designed in 
such a way to lead slower substitution kinetics due to glu-
tathione competition through dissociative thiol substitu-
tion, instead of an associative mechanism like in cisplatin 
[5, 14]. Lower toxicity of picoplatin compared to cisplatin 
has been confirmed, particularly regarding nephro- and 
neurotoxicity, showing anticancer activity in the cisplatin 
resistance cancer lines such as lung, colorectal, and prostate 
cancers. Picoplatin treatments in combination with 5-fluo-
rouracil (FU) and leucovorin for colorectal cancer, as well 
as in combination with docetaxel for prostate cancer, have 
reached phases I and II of clinical trials [5].
In recent years, in order to improve delivery of Pt(II) 
drugs, reduce toxicity and get better drug tolerance profile, 
new liposomal and polymer based drug delivery systems 
have been developed [15–18]. Pt(II) drugs encapsulated in 
a liposome or in specially designed polymer have found 
various advantages over Pt(II) drugs: they have better solu-
bility, biocompatibility, better membrane permeability, drug 
stability within delivery systems, and higher retention time.
Prolindac is a drug-delivery system of oxaliplatin, en-
capsulated in hydrophobic biocompatible polymer hy-
droxypropylmethaacrylamide (HPMA), which, compared 
to oxaliplatin, have shown higher activity and lower toxic-
ity (neurotoxicity) in various human cancers in phase II of 
clinical trials (Figure 1) [4, 5, 18]. Clearly enough, HPMA 
polymer has the role of delivery system of oxaliplatin to the 
target cancer cells where it undergoes decomposition due 
to the low pH value within the cancer cells [4]. Prolindac 
has shown significant anticancer activity for treatments of 
breast, ovarian, lung, and prostate cancers, especially for 
metastatic melanoma and ovarian cancer.
Liposomal formulations of cisplatin (lipoplatin, TRX-
20), oxaliplatin (lipoxal), and an oxaliplatin analogue 
(aroplatin) have been created recently (Figure 1) [16, 17]. 
Lipoplatin has overcome phases I, II, and III of clinical 
trials showing remarkable anticancer properties due to 
small sized particles (90 to 130 nm), causing easier cross 
through cell membranes and consequently fewer side ef-
fects, particularly negligible nephrotoxicity, ototoxicity 
and neurotoxicity. Lipoplatin has high anticancer activ-
ity against metastatic tumors, particularly prostate, colon, 
gastric, and lung cancers [16]. Cisplatin encapsulated in 
cationic lipid polyethylene glycol-coated liposomes (TRX-
20) has shown increased delivery time to target molecules, 
high bioavailability, and anticancer activity in treatments 
of some metastatic cancers, especially refractory prostate, 
colon, gastric and lung cancers [5].
In recent years, polinuclear bridged platinum complexes 
(Figure 1) have also attracted particular attention, since 
they have two or three platinum centers which are able to 
bind at several sites along the DNA helix, causing more se-
vere DNA damage and being more effective against cancer 
cells as compared to cisplatin analogues [4, 15].
RUTHENIUM ANTICANCER COMPLEXES
Non-platinum complexes based on ruthenium, gold, pal-
ladium or titanium, have been investigated in the quest 
for compounds with lower toxicity and higher selectivity 
compared to cisplatin. Ruthenium compounds have specific 
physicochemical properties that make them promising as 
anticancer agents: (a) activation by reduction (from Ru(III) 
to Ru(II)), (b) different coordination geometry compared to 
platinum, and (c) favorable ligand-exchange kinetics [19]. 
In the last two decades, many papers have documented 
the great anticancer potential of ruthenium complexes, 
both in vivo and in vitro. Three of the most investigated ru-
thenium drugs are NAMI-A ([H2Im][trans-RuCl4(DMSO)
(Im)]) (Figure 2a), KP1019 (trans-[tetrachlorobis(1H-in-
dazole)ruthenate(III)]) (Figure 2b), and sodium derivative 
of KP1019, KP1339 (Figure 2c). All three compounds have 
entered Phases I and II of clinical trials.
NAMI-A has significant efficacy in inhibiting tumor me-
tastasis [20], while this compound, in vitro, has low potency 
in terms of cytotoxicity towards cancer cells. The mode 
of action of NAMI-A is not clear and many papers docu-
mented potency of this complex for binding to DNA and 
RNA [20, 21]. KP1019 synthesized by the Keppler group 
entered clinical trials [22], but the main problem in the 
Figure 2. NAMI-A (a), KP1019 (b) and KP1339 (c)
Figure 3. General formula of organoruthe-
nium complexes (a) and (b)
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clinical investigations for KP1019 is its low solubility under 
physiological conditions. With better solubility, sodium salt 
KP1339, is currently undergoing clinical trials [23].
Arene ruthenium(II) complexes, general formula [(η6-
arene)Ru(X)(Y)(Z)], where X and Y can be two mono-
dentate or one bidentate ligand (Figure 3a and 3b), were 
first investigated in the field of anticancer compounds by 
Sadler and Dyson [24]. The presence of the chelating li-
gand provides the additional stability of the whole struc-
ture. Monodentate ligand Z is a good leaving group (in the 
most cases halogen). These complexes showed piano stool 
geometry, where arene is benzene (ben) or methylisopropyl 
benzene (cym) or biphenyl (bip) or dihydroanthracene 
(dha) which provide hydrophobicity of molecule and en-
sure the entry of the complexes in the cell [24]. It was 
shown for some complexes of this type that the cytotoxicity 
increases with the arene moiety size because of the greater 
ability of the arene to intercalate into DNA. Also, aromatic 
part stabilizes ruthenium center in oxidation state + 2. For 
the complexes general formula, [(η6-arene)Ru(en)Cl]+, (en 
= etylendiamine) it has been shown that cytotoxicity in-
creases in the series arene: benzene <p-cymene <bipheny
l<dihydroanthrancene<tetrahydroantracene [25].
CONCLUSION
Cisplatin has so far been the most used chemotherapeutic 
agent, regardless of its disadvantages such as cumulative 
toxicity and development of cancer cell resistance. With 
aim to overcome these side effects, many novel platinum 
complexes have been synthesized and studied. Regrettably 
enough, only about 20 out of thousands of new platinum 
compounds have reached clinical trials. After development 
of second (carboplatin) and third (oxilplatin) generation 
of platinum(II) drugs, by replacement of chloride and am-
mine ligands in cisplatin respectively, further research has 
led to polymer or liposome formulations of platinum(II)
drugs and new dinuclear and oligonuclear platinum com-
plexes. In recent years, ruthenium complexes have had a huge 
potential for application in cancer therapies, being the only 
non-platinum compounds that have entered clinical trials.
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САЖЕТАК
Карциноми су један од водећих узрока смртности светске 
популације. Процењује се да ће у наредне две деценије око 
20 милиона људи у свету имати постављену дијагнозу кар-
цинома. Главни задатак медицинске хемије јесте добијање 
нових хемиотерапеутских агенаса са бољим антиканцер-
ским својствима.
Cisplatin се примењује у онкологији од 1978. године, као 
први хемиотерапеутски агенс који специфично долази у 
интеракцију са молекулима ДНК, доводи до ДНК оштећења 
и узрокује ћелијску смрт. Од када је цисплатин нашао при-
мену у терапији карцинома, расте интересовање за новим 
једињењима који садрже метале, а посебно за комплексима 
платине и рутенијума, са већом антиканцерском активношћу 
и мање нежељених дејстава у поређењу са цисплатином. 
Carboplatin и oxaliplatin су се показали ефикасним у третма-
ну неких типова карцинома резистентних на цисплатин. Са 
циљем превазилажења резистентности на ове Pt(II)-лекове, 
најпре су комплекси платине (satraplatin и picoplatin) нашли 
примену као први орални лекови, као и комбиноване тера-
пије појединих Pt(II)-лекова (cisplatin, picoplatin) са специ-
фично резистентним модулаторима. Последњих година ди-
зајниране су нове полимерне и липозомалне формулације 
лекова платине (prolindac, lipoplatin, lipoxal, aroplatin) због 
боље циљне испоруке лека до туморских ћелија и њихове 
смањене токсичности. Комплекси рутенијума имају велику 
могућност примене у терапији карцинома. Ова једињења 
показују добру антиканцерску активност, како in vitro, тако 
и in vivo, а два комплекса рутенијума (KP1019 и NAMI-A) по-
казала су добре резултате у клиничким испитивањима.
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